Koshinski Asset Management
IKT icon

Koshinski Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Koshinski Asset Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,613
Closed -$37.9K – 635
2023
Q1 		$37.9K Sell
9,613
-1,283
-12% -$5.35K ﹤0.01% 553
2022
Q4 		$32.7K Hold
10,896
– – ﹤0.01% 601
2022
Q3 		$59K Hold
10,896
– – 0.01% 544
2022
Q2 		$49K Buy
+10,896
New +$64.3K ﹤0.01% 591

Other funds holding IKT

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Koshinski Asset Management's IKT Position: Q2 2023 in Review

Koshinski Asset Management sold out of Inhibikase Therapeutics (IKT) in Q2 2023, closing a stake of 9,613 shares — an estimated $37.9K sold.

Koshinski Asset Management first reported a position in IKT in Q2 2022 and held it in 4 quarters. The position peaked at $59K in Q3 2022. 14 funds tracked by Wall St. Rank hold IKT as of Q2 2023.

  • Koshinski Asset Management reported no remaining Inhibikase Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Koshinski Asset Management sold 9,613 Inhibikase Therapeutics shares in Q2 2023, an estimated $37.9K.
  • Koshinski Asset Management first reported a position in Inhibikase Therapeutics in Q2 2022 and held it in 4 quarters.
  • Koshinski Asset Management's Inhibikase Therapeutics position peaked at $59K in Q3 2022.
  • 14 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2023.

Based on Koshinski Asset Management's 13F filing for Q2 2023, filed 28 Jul 2023.